Synektik strategy in medical imaging, shares on Warsaw radar

By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-23, 17:30.

Synektik (PLSYNEK00016) remains a niche name on the Warsaw Stock Exchange, with its business closely linked to hospital spending on advanced imaging and oncology diagnostics in Central Europe. The company focuses on medical imaging systems and radiopharmaceuticals for cardiology and oncology, according to its own corporate profile. Synektik investor relations overview

Position in European medtech landscape

Synektik operates in the broader European medical technology space alongside larger peers such as Siemens Healthineers and Philips, which also supply imaging systems to hospitals worldwide. Reuters coverage of Siemens Healthineers The Polish group concentrates on the domestic and regional market, supplying equipment and services to cardiology and oncology centers.

The company is active in nuclear medicine and radiopharmaceutical production, segments that benefit from rising volumes in PET-CT and SPECT-CT diagnostics across Europe. Public healthcare investment programs in Poland and neighboring countries typically span several years, creating medium-term visibility for equipment and service contracts, as sector reports on Central European healthcare spending indicate. Financial Times analysis of European hospital investment

Analyst and market-view framework

While Synektik is too small for regular coverage by major international banks, the medtech and imaging sector is tracked by houses such as UBS, JPMorgan and Berenberg, which highlight long-term demand for diagnostic capacity in aging societies. UBS healthcare equipment report These sector studies point to structural drivers like demographic change, oncology incidence and the integration of AI into image analysis.

On the equity side, Polish healthcare and technology names are followed on the Warsaw Stock Exchange with a focus on earnings visibility, reimbursement frameworks and exposure to public tenders, as local broker commentaries underline. Reuters report on Polish equity market focus For companies like Synektik, the combination of equipment sales, long-term service contracts and radiopharmaceutical supply agreements shapes revenue patterns.

How Synektik makes its money

Synektik generates revenue from three main activities: the sale and servicing of advanced imaging equipment such as PET-CT and SPECT cameras, the production and distribution of radiopharmaceuticals for cardiology and oncology diagnostics, and integration projects for hospital imaging infrastructure, as outlined in its corporate materials. Synektik description of products and services

Where the shares trade today

The Synektik shares (PLSYNEK00016) trade on the Warsaw Stock Exchange in Polish zloty; current price and market capitalization data are available on the exchange’s official quote pages and the company’s investor-relations site.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any financial instruments. All information is based on publicly available sources believed to be reliable, without any guarantee of completeness or accuracy.